The effect of soy isoflavone on bone mineral density in postmenopausal Taiwanese women with bone loss: a 2-year randomized double-blind placebo-controlled study - PubMed (original) (raw)
Randomized Controlled Trial
. 2012 May;23(5):1571-80.
doi: 10.1007/s00198-011-1750-7. Epub 2011 Sep 8.
Affiliations
- PMID: 21901480
- PMCID: PMC3332377
- DOI: 10.1007/s00198-011-1750-7
Randomized Controlled Trial
The effect of soy isoflavone on bone mineral density in postmenopausal Taiwanese women with bone loss: a 2-year randomized double-blind placebo-controlled study
T Y Tai et al. Osteoporos Int. 2012 May.
Abstract
The treatment of 300-mg/day isoflavones (aglycone equivalents) (172.5 mg genistein + 127.5 mg daidzein) for 2 years failed to prevent lumbar spine and total proximal femur bone mineral density (BMD) from declining as compared with the placebo group in a randomized, double-blind, two-arm designed study enrolling 431 postmenopausal women 45-65 years old.
Introduction: This study evaluated the effects of soy isoflavones on bone metabolism in postmenopausal women.
Methods: Four hundred and thirty-one women, aged 45-65 years, orally consumed 300-mg/day isoflavones (aglycone equivalents) or a placebo for 2 years in a parallel group, randomized, double-blind, two-arm study. Each participant also ingested 600 mg of calcium and 125 IU of vitamin D(3) per day. The BMD of the lumbar spine and total proximal femur were measured using dual-energy X-ray absorptiometry at baseline and every half-year thereafter. Serum bone-specific alkaline phosphatase, urinary N-telopeptide of type 1 collagen/creatinine, and other safety assessments were examined regularly.
Results: Two hundred out of 217 subjects in the isoflavone group and 199 out of 214 cases in placebo group completed the treatment. Serum concentrations of isoflavone metabolites, genistein and daidzein, of the intervention group were remarkably elevated following intake of isoflavones (p < 0.001). However, differences in the mean percentage changes of BMD throughout the treatment period were not statistically significant (lumbar spine, p = 0.42; total femur, p = 0.39) between the isoflavone and placebo groups, according to the generalized estimating equation (GEE) method. A significant time trend of bone loss was observed at both sites as assessed by the GEE method following repeated measurement of BMD (p < 0.001). Differences in bone marker levels were not significant between the two treatment groups.
Conclusion: Treatment with 300-mg/day isoflavones (aglycone equivalents) failed to prevent a decline in BMD in the lumbar spine or total femur compared with the placebo group.
Figures
Fig. 1
Enrollment flow chart of patients. Superscript a National Taiwan University Hospital is abbreviated as NTUH, Changhua Christian Hospital as CCH, and National Cheng Kung University Hospital as NCKUH. Superscript b AE denotes adverse events
Similar articles
- Long-term consumption of isoflavone-enriched foods does not affect bone mineral density, bone metabolism, or hormonal status in early postmenopausal women: a randomized, double-blind, placebo controlled study.
Brink E, Coxam V, Robins S, Wahala K, Cassidy A, Branca F; PHYTOS Investigators. Brink E, et al. Am J Clin Nutr. 2008 Mar;87(3):761-70. doi: 10.1093/ajcn/87.3.761. Am J Clin Nutr. 2008. PMID: 18326616 Clinical Trial. - The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis.
Zhu HM, Qin L, Garnero P, Genant HK, Zhang G, Dai K, Yao X, Gu G, Hao Y, Li Z, Zhao Y, Li W, Yang J, Zhao X, Shi D, Fuerst T, Lu Y, Li H, Zhang X, Li C, Zhao J, Wu Q, Zhao SJ. Zhu HM, et al. Osteoporos Int. 2012 Apr;23(4):1317-27. doi: 10.1007/s00198-011-1577-2. Epub 2011 Apr 20. Osteoporos Int. 2012. PMID: 21505910 Clinical Trial. - Isoflavone intervention and its impact on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials.
Inpan R, Na Takuathung M, Sakuludomkan W, Dukaew N, Teekachunhatean S, Koonrungsesomboon N. Inpan R, et al. Osteoporos Int. 2024 Mar;35(3):413-430. doi: 10.1007/s00198-023-06944-y. Epub 2023 Oct 25. Osteoporos Int. 2024. PMID: 37875614 Review. - Soy protein consumption and bone mass in early postmenopausal Chinese women.
Ho SC, Woo J, Lam S, Chen Y, Sham A, Lau J. Ho SC, et al. Osteoporos Int. 2003 Oct;14(10):835-42. doi: 10.1007/s00198-003-1453-9. Epub 2003 Aug 14. Osteoporos Int. 2003. PMID: 12920508 Review.
Cited by
- Plant-derived natural medicines for the management of osteoporosis: A comprehensive review of clinical trials.
Karimi SM, Bayat M, Rahimi R. Karimi SM, et al. J Tradit Complement Med. 2023 Aug 5;14(1):1-18. doi: 10.1016/j.jtcme.2023.08.001. eCollection 2024 Jan. J Tradit Complement Med. 2023. PMID: 38223808 Free PMC article. Review. - Effects of Isoflavonoid and Vitamin D Synergism on Bone Mineral Density-A Systematic and Critical Review.
Miedziaszczyk M, Maciejewski A, Idasiak-Piechocka I, Karczewski M, Lacka K. Miedziaszczyk M, et al. Nutrients. 2023 Dec 5;15(24):5014. doi: 10.3390/nu15245014. Nutrients. 2023. PMID: 38140273 Free PMC article. Review. - Equol and Resveratrol Improve Bone Turnover Biomarkers in Postmenopausal Women: A Clinical Trial.
Corbi G, Nobile V, Conti V, Cannavo A, Sorrenti V, Medoro A, Scapagnini G, Davinelli S. Corbi G, et al. Int J Mol Sci. 2023 Jul 27;24(15):12063. doi: 10.3390/ijms241512063. Int J Mol Sci. 2023. PMID: 37569440 Free PMC article. Clinical Trial. - An Updated Review of Soy-Derived Beverages: Nutrition, Processing, and Bioactivity.
Olías R, Delgado-Andrade C, Padial M, Marín-Manzano MC, Clemente A. Olías R, et al. Foods. 2023 Jul 11;12(14):2665. doi: 10.3390/foods12142665. Foods. 2023. PMID: 37509757 Free PMC article. Review. - Isoflavone Consumption and Risk of Breast Cancer: An Updated Systematic Review with Meta-Analysis of Observational Studies.
Yang J, Shen H, Mi M, Qin Y. Yang J, et al. Nutrients. 2023 May 21;15(10):2402. doi: 10.3390/nu15102402. Nutrients. 2023. PMID: 37242286 Free PMC article.
References
- Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333. doi: 10.1001/jama.288.3.321. - DOI - PubMed
- Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O’Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291:1701–1712. doi: 10.1001/jama.291.14.1701. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical